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Blends of aqueous dispersion of a hydrophobic and hydrophilic polymer, namely Surelease®: 
hydroxypropyl methylcellulose (Surelease®: HPMC E15) were used as coating materials to control the 
drug release from coated pellets of the highly water soluble drug metoprolol succinate. Varying the polymer 
blends, ranges of drug release patterns were obtained at pH 6.8. The present study dealt with diffusion 
of drug through plasticized Surelease®/ hydroxypropyl methylcellulose (HPMC E15) films prepared by 
coating of drug and polymers onto non-pareil seeds using the solution layering technique. The release 
of metoprolol succinate from coated pellets was decreased with increased coating load of polymer. The 
optimized formulation was obtained by 32 full factorial design. The release profile revealed that the 
optimized formulation follows zero order release kinetics. The stability data showed no interaction for 
storage at 25oC and 60% relative humidity.
Uniterms: Pellets. Nonpareil seeds. Surelease®. HPMC E15. Coating. Solution layering technique. 
Cushning agent. Metoprolol succinate.
Misturas das dispersões aquosas de polímero hidrofóbico e de polímero hidrofílico, a saber, Surelease®: 
hidroxipropil metilcelulose (Surelease®: HPMC E15), foram utilizadas como material de revestimento 
para controlar a liberação de fármacos de péletes revestidos de fármaco altamente solúvel, o succinato de 
metoprolol. Variando as misturas de polímeros, obtiveram-se faixas de padrão de liberação do fármaco 
em pH 6,8. O presente estudo tratou da difusão do fármaco através de filmes de Surelease®/hidroxipropil 
metilcelulose(HPMC E15), preparados pelo revestimento do fármaco e dos polímeros em sementes 
nonpareil, utilizando técnica de solução em camada. A liberação de succinato de metoprolol dos péletes 
revestidos diminuiu com o aumento da carga de polímero de revestimento. A formulação otimizada foi 
obtida por planejamento fatorial 32. O perfil de liberação revelou que a formulação otimizada segue 
a cinética de liberação de ordem zero. Os dados de estabilidade mostraram não haver interação por 
armazenamento a 25 oC e umidade relativa de 60%. 
Unitermos: Péletes. Nonpareil. Surelease®. HPMC E15. Revestimento. Técnica da solução em camada. 
Agente de cushning. Succinato de metoprolol.
INTRODUCTION
Developing oral sustained release systems for freely 
water soluble drugs having strong first pass metabolism 
has always posed a challenge to the pharmaceutical tech-
nologist. Most of these highly water soluble drugs, if not 
formulated properly, are released at a high rate and are 
likely to produce toxic concentrations when administered 
orally (Lian-Dong, Yang, Xing, Qian, 2006). Polymeric 
film coatings are often used for achieving sustained release 
of an active substance from pharmaceutical formula-
tion because a coated dosage form enables prolonged 
and precise release of drug with good reproducibility 
(Sousa, Sousa, Moura, Newton, 2002; Vaithiyalingam, 
Khan, 2002). One of the most widely used hydrophobic 
polymers in pharmaceutical film coating is ethyl cellu-
lose (Surelease®), due to its convenient film formability, 
good physiochemical properties and minimum toxicity 
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(Mcginity, 1997). Surelease® is a good polymer for modi-
fied release coating. The polymer is usually used in com-
bination with a secondary polymer such as hydroxypropyl 
methylcellulose (HPMC E15) which confers the film a 
more hydrophilic nature and alters its structure by virtue 
of pores and channels through which the drug substance 
can diffuse more easily to control the release properties of 
a drug formulation (Aulton, Bdul-Razzak, Hogan, 1981). 
Surelease® containing plasticizer is essential to enhance 
film forming characteristics, workability and serviceability 
(Frenning, Tuno´N, Alderborn, 2003). Pellets as a drug 
delivery system offer not only technological advantages 
but also better flow properties, less friable dosage form, 
narrow particle size distribution, ease of coating, and 
uniform packing (Siepmann, Siepmann, Walther, Macrae, 
Bodmeier, 2005). It also has therapeutic advantages such 
as less irritation of the gastrointestinal tract, a low risk of 
side effects associated with dose dumping and reduction 
of the variation in gastric emptying rates (Evdokia, 2000). 
Coating of pellets in a coating pan with a polymer is often 
used as a means of controlling the drug release rate from 
extended release formulations. The coated pellets can be 
compacted into multiple unit tablets or used to fill hard 
gelatin capsules. Both formulations are normally intended 
to release intact reservoir pellets after administration; thus 
the overall drug release rate is determined by the release 
rate from single pellet units.
Metoprolol succinate, a white crystalline powder, is 
freely soluble in water. Since the solubility of metoprolol 
succinate is lower at neutral pH, compared to acidic pH, 
it is released by the mechanism of diffusion through an 
insoluble polymer film (Ye, Rombout, 2007). It is a cardio 
selective β-blocker that has been classified as a class I 
substance according to the Biopharmaceutics Classifica-
tion System, meaning that it is highly soluble and highly 
permeable. The drug is readily and completely absorbed 
throughout the intestinal tract (Rahman, Yuen, 2006) but 
is subjected to extensive first pass metabolism resulting 
in incomplete bioavailability (about 50%). After a single 
oral dose, peak plasma concentration occurs after about 
1 to 2 h. The drug is eliminated within 3 to 4 h which, 
depending on therapeutic activity, makes it necessary to 
administer the formulation up to 4 times daily. Based on 
these properties and well defined relationship between 
the beta blocking effect and plasma drug concentration, 
metoprolol lends itself to a sustained release formulation.
The goal of this study was to develop a sustained 
release multiparticulate dosage form as a tablet of me-
toprolol succinate to reduce the dosing frequency from 
three times to once a day, and to study the stability of these 
formulations. Sustained release multiparticulate tablets of 
metoprolol succinate were prepared by the compression 
technique in which sustained release pellets were mixed 
with the cushning agent micro-crystalline cellulose (Avi-




The following chemicals were procured from com-
mercial suppliers: 
Surelease® NG, E-7-1905, (Colorcon Asia Pvt. Ltd., 
Goa); hydroxypropyl methylcellulose (HPMC) E15, po-
tassium dihydrogen phosphate, hydrochloric acid 35.4%, 
sodium hydroxide, magnesium stearate , talc (all Loba 
Chemie Pvt. Ltd., Mumbai), Indion 414 (Ion Exchange 
India Limited, Mumbai, India), microcrystalline cellu-
lose (Avicel® PH102, Que Pharma Pvt. Ltd., Wadhwan), 
non-pariel seeds (Salus Pharmaceuticals, Ahmedabad), 
metoprolol succinate (Glenmark Pharma Pvt. Ltd., Goa). 
Distilled water was used throughout the work. All other 
reagents were of analytical grade.
Methods
Preparation of sustained release pellets of metoprolol 
succinate
· Preparation of drug pellets
Metoprolol succinate 20% w/v was mixed with a 
1% w/v aqueous binder solution of polyvinyl pyrrolidone 
(PVP) K30 and 2% w/v talc with continuous stirring (Rah-
man, Yuen, 2006). This drug solution was sprayed onto 
200 g of uncoated pellets as non pariel seeds of 14/16 mesh 
of size 850-1100 µm by the solution layering technique in 
a coating pan (Instacoat R & D Coater, Ideal Cures Pvt. 
Ltd., Mumbai, India). The drug layering conditions were 
as shown in Table I.
· Preparation of polymer dispersion
An aqueous dispersion of Surelease® was diluted 
to 15% w/v with distilled water. Similarly, a 5% solution 
of HPMC E15 was prepared in water by dispersing the 
powder of HPMC E15 in 50 ml of preheated water (80-
90oC) and then diluting it with an additional 50 ml of cold 
water. The solution was kept overnight. Varying polymer 
blends of Surelease® and HPMC E15 were selected for the 
polymer dispersion of sustained release formulation. To 
reduce foam, the anti-foaming agent oleic acid was added 
to the dispersion.
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Coating of drug pellets with polymer dispersion
In a mixture of dispersion of varying concentrations 
of Surelease® and HPMC E15, a small quantity of talc (2% 
w/v) was added as an anti-adherent to the coating mixture. 
The mixture was stirred using a magnetic stirrer prior to 
and throughout the coating process. The drug pellets (200 
g) were coated at different coating loads by the solution 
layering technique. Coating parameters were set as shown 
in Table I. The coating fluid was sprayed onto the pellets 
with an intermittent drying time of 5 min in a coating pan. 
Formulation optimization (factorial design)
The optimization of batch was carried out by 32 full 
factorial design as shown in Table II.
Different formulation codes were assigned to the 
batches of ratios of Surelease®: HPMC E15 and polymer 
coating loads. Formulation code F1 indicated the content 
of Surelease® and HPMC E15 in the ratio of 70:30 of 15% 
coating load. Formulation codes F2 to F9, assigned to the 
varying blends of polymer and coating load, are as shown 
in Table III. In the factorial design, dependent variables 
are Y1 as drug release (%), Y2 as t50% (h), Y3 as t80% (h) 
and independent variables are X1 as ratio of Surelease®: 
HPMC E15, and X2 as coating load (%).
Curing time
After coating, the pellets were further cured at 40oC 
at 75% relative humidity for 24 h (Lecomte, 2004)









X1 70:30 80:20 90:10:00
Coating level (%) X2 15 20 25
Levels -1, 0 and +1 indicates lower, middle and higher level 
for factorial data
TABLE I - Coating parameters required during coating
Conditions Preheating Coating Drying
Inlet air temperature(°C) 55-60 65-70 50
Product temperature(°C) 40-45 50-55 40-45
Outlet air temperature(°C) 35-40 40-45 40-45
Spray rate (ml/min) - 3-4 -
Atomizing air pressure(psi) - 20 -
Pan speed (rpm) 35-37 35-37 35-37













X1- ratio of combinations of Surelease®: HPMC E15; X2-% 
coating thickness
Characterization of pellets
Non pareil seeds were evaluated visually to check 
the spherical nature. The flow property of these was stu-
died using the following tests:
· Carr’s index
Carr’s index value for uncoated pellets and coated 
pellets were determined using formula (Aulton M., 2002):
                                  
(Tapped density - Fluff density)Carr’s Index (%) = ————————————— x 100
                      Tapped density
· Angle of repose
The static angle of repose of uncoated pellets and 
coated pellets was measured by the fixed funnel and 
free-standing cone method (Aulton M., 2002) using the 
formula: 
Angle of repose (θ) = tan -1 h/r
where: h-height of the heap; r-radius of the flat surface 
occupied by pellets 
· Drug content
Sustained release pellets (400 mg) of MS were 
triturated and dissolved in 100 ml distilled water. Further 
dilutions were made using pH 6.8 phosphate buffer so-
lutions. The amount of drug content was estimated UV 
spectrophotometrically (JASCO V-530, Japan) at 274 nm.
In vitro dissolution
Dissolution testing of formulations F1-F9 was per-
formed using USP XXVIII type I. The test was performed 
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using 500 ml solution of pH 6.8 phosphate buffer main-
tained at temperature 37 ± 0.5°C stirred at a speed of 50 
rpm (United State Pharmacopoeia, 2005). A sample of 5 
ml was taken out at an interval of 0.5, 1, 1.5, 2, 3, 4, 6, 8, 
10, 12, 13, 14, 20, 21, 22, 23 and 24 h and immediately 
replaced with 5 ml fresh pH 6.8 phosphate buffer solution 
to maintain sink conditions in the dissolution jar. The drug 
content was analyzed at 274 nm using a UV spectropho-
tometer (Jasco, Japan).
Sustained release metoprolol succinate tablets
Sustained release pellets having a cushning agent 
of micro-crystalline cellulose and superdisintegrant of 
Indion 414 were compressed in a six stations rotary tablet 
machine (General Machinery Co., Mumbai) equipped 
with flat-faced punch with a diameter of 9 mm and length 
of 16mm after lubrication of the punch and die by dusting 
with magnesium stearate to achieve a 700 mg multiparti-
culate sustained release tablet (Table IV).
Cushning agents protected the polymer coat while 
superdisintegrant released the pellets from the multipar-
ticulate tablet. Multiparticulate sustained release tablets 
were evaluated for hardness, friability, drug content, 
disintegration test and dissolution test.
Scanning electron microscopy
The morphology of the surfaces and cross sections 
of the coated pellets were examined before and after com-
pression by scanning electron microscopy (SEM) (Tunon 
A., 2003). The dried samples were coated by platinum 
coating using an auto fine coater (JEOL-JFC 1600, Japan) 
and then observed under different magnifications with 
an analytical scanning electron microscope (JEOL-JSM 
6360A, Japan).
Stability testing protocol
Coated pellets were packaged and sealed in 20 g 
quantities in high density amber colored bottles. These 
TABLE IV - Composition of multiparticulate sustained release 
tablet
Ingredients Quantity (mg)
coated sustained release pellets 227.27





bottles were then placed inside stability testing instruments 
(Scientific equipment Pvt. Ltd., Mumbai) previously 
equilibrated to 25ºC/60% relative humidity (RH). At pre-
determined time intervals, bottles were pulled out from 
stations and tested for dissolution (Shao, 2002).
RESULT AND DISCUSSION
Physical characteristics of pellets
Non pareil seeds and sustained release pellets having 
Carr’s index value in the range 14-16% and angle of repose 
of 22-240 showed good flow property (Aulton, 2002). 
Drug Content
Amount of drug in pellets was found to be 11% 
estimated spectrophotometrically.
In vitro dissolution data analysis
In 32 full factorial design, various factors were stu-
died using all the possible combinations, as it was consi-
dered to be most efficient for estimating the influence of 
individual variables (main effects) and their interactions, 
using minimum experimentation (Figure 1).
From the dissolution profile, it was concluded 
that batches F1-F3 of the ratio 70:30 released drug from 
97.21±1.91 % to103.26±1.13% for up to 6-7 h, respecti-
vely. Batches F4-F6 of the ratio 80:20 released drug from 
98.57±0.49% to 104.9±2.25% up to 20-24 h, respecti-
vely, and F7-F9 of the ratio 90:10 released drug from 
88.08±2.14% to 95.68±0.6 % up to 20-24 h, respectively 
(Table V). 
FIGURE 1 - Dissolution profile of sustained release formulations 
of metoprolol succinate pellets{Mean (N=3)}.
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The results are the mean and standard deviation 
(S.D.) of five replicates.
Study of regression coefficient (r2) of different 
kinetic models
Different kinetic models were studied from disso-
lution profile of the different formulations of metoprolol 
succinate sustained release pellets as shown in Table VI.
The general polynomial equation for percent release 
in terms of coded factors using multiple linear regression 
analysis is -
Y = β0 + β1 X1 + β2 X2 + β3X1X2 + β4X1 
2+ β 5 X 2
2+ β 6 X1 
X 2
2+ β 7 X2 X1 
2+ β 8 X1
2X2
2
Where Y represents the measured response and X1 
represents the value of the factors. β0, β1, β2… are the con-
stants representing the intercept, coefficients of first-order 
TABLE V - Percent cumulative release of t50% and t80% of metoprolol succinate pellets
Sr.No. Formulations Polymer ratio Coating load % Cumulative 
release (S.D.)
Average t50%(h) Average t80%(h)
1 F1 70:30 15 102.13±2.65 1.17 1.83
2 F2 70:30 20 103.26±1.13 2.33 4.5
3 F3 70:30 25 97.21±1.92 4 5.5
4 F4 80:20 15 104.9±2.25 2.83 6.83
5 F5 80:20 20 99.17±0.71 8.17 14.17
6 F6 80:20 25 98.57±0.49 8.42 15.83
7 F7 90:10 15 95.68±0.6 3.17 5.25
8 F8 90:10 20 94.17±1.69 7.08 15.5
9 F9 90:10 25 88.08±2.14 7.17 16
TABLE VI - Kinetic models showing drug release pattern of F1-F9 formulations






Higuchi (r2) Hixen-Crowel (r2)
F1 0.9355 0.8397 0.9349 0.9633 0.8762
F2 0.9708 0.8998 0.9719 0.97 0.9197
F3 0.9635 0.8848 0.9649 0.9767 0.9084
F4 0.9714 0.9026 0.975 0.9767 0.9277
F5 0.9967 0.9488 0.9803 0.9933 0.9402
F6 0.9917 0.8715 0.9611 0.99 0.9381
F7 0.9 0.7997 0.917 0.9567 0.849
F8 0.9783 0.8147 0.884 0.98 0.8585
F9 0.9853 0.9295 0.9792 0.99 0.9135
terms, and coefficients of second-order quadratic terms, 
respectively. Further data was obtained by putting design 
experts results into the above polynomial equation.



















t80% = +9.49+4.15*X1-1.39* X1 
2+3.90* X1-0.95* X2 
2 
+1.77* X1 X2-0.30*X1
2 X2-0.67* X1 X2 
2-003 * X1 
2 X2 
2 
Table VI indicates the best-fit model for each for-
mulation. The model was calculated based on the value of 
coefficient of regression closest to 0.9999. Out of a total 
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of nine formulations, F1, F3, F4, F9 followed the Higuchi 
model. Formulations F2, F5, F6, F7, and F8 followed 
zero- order kinetics.
Comparative study of dissolution profile of 
optimized formulation and marketed formulation
From data obtained by the feasibility search method, 
the formulation batch of ratio 80:20 of coating load 22.5% 
was selected for further study. The dissolution profile of 
the optimized formulation of sustained release pellets was 
compared with the marketed matrix tablet formulation as 
shown in Figure 2 whereas kinetics parameters studied are 
shown in Table VII. Similarity factor (f2) was calculated 
using PCP-DISSO software and found to be 79.43.
Metoprolol succinate sustained release 
multiparticulate tablet
Characterization of metoprolol succinate 
multiparticulate sustained release tablet
The evaluation parameters of multiparticulate tablet 
of tablet size, tablet thickness, weight variation, hardness, 
friability, drug content and uniformity of content were as 
depicted in Table VIII.
Dissolution profile
The dissolution profile of multiparticulate sustained 
release tablet was compared with sustained release marke-
ted matrix tablet. The similarity (f2) factor was calculated 
using PCP-DISSO software and found to be 76.46. 
From the value of regression coefficient (r2), the best 
fit model was found to follow zero order kinetics with r2 
as 0.9939. The t50% and t80% of multiparticulate tablet was 
found to be 7.2 ± 0.4 h and 13.5 ± 0.5 h, respectively 
(Figure 3).
Scanning electron microscopy of non pareil seeds, 
coated pellets and compressed sustained release 
pellets
The coatings of non pareil seeds, coated pellets and 
sustained release pellets after compression were studied by 
scanning electron microscopy at both low and high magni-
fications. The coated pellets at low magnification appeared 
as spherical discrete units (Figure 4, Figure 6 and Figure 9) 
TABLE VII - Kinetic models showing drug release pattern of formulated and marketed formulation






Prepared formulation Zero-order kinetics 0.9954 93.87±0.5036 6.5±0.4 12.75±0.5
Marketed formulation Higuchi 0.9991 94.24±0.4866 8.0±0.5 13.5±0.5
TABLE VIII - Evaluation parameters of multiparticulate tablet
Tablet size 15.1 ± 0.08 mm in length and 
9.8 ± 0.06 mm in width
Tablet thickness 5 ± 0.05 mm
Weight variation 700.15± 27mg
Hardness 4.5-5.5 kg/cm2
Friability 1.50%
Drug content 99.28 ± 1.5%
Uniformity of content 99.28 ± 1.2%
FIGURE 2 - Comparative study of dissolution profile of 
optimized formulation and marketed Formulation.
FIGURE 3  -  Dissolution profile of sustained release 
multiparticulate tablet formulation.
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and the surface morphology at high magnification was not 
homogenous or smooth, acting as entrance or exit points 
for the dissolution medium to dissolve the drug (Figure 5, 
Figure 7, Figure 8 and Figure 10).
Stability data
Stability data revealed that pellets were stable at 
25ºC/60% relative humidity (RH) for short term stability 
of three months. The amount of drug in the pellets was 
found to be the same after three months (Figure11).
The present study investigated the coating effect 
of a combination of Surelease® and HPMC E15 on drug 
release of highly water soluble metoprolol succinate in a 
coating pan. Coated pellets showed good flow properties 
FIGURE 4 - Scanning electron microscopy of non pareil seeds 
(X80).
FIGURE 5 - Scanning electron microscopy of non pareil seeds 
(X1000).
FIGURE 6 - Scanning electron microscopy of polymer coated 
pellets of an optimized batch F6 (X80). 
FIGURE 7 - Scanning electron microscopy of polymer coated 
pellets of an optimized batch F6 (X1000).
for the development of a tablet as a multiparticulate drug 
delivery system. This film, formed by the combination of 
these polymers, strongly retarded the permeation of me-
toprolol, a highly soluble drug, for extended release. The 
optimization results revealed that metoprolol succinate 
sustained release pellet of Surelease® and HPMC E15 
of 80:20 at a 22.5 % coating load showed comparatively 
better drug release of zero order kinetics than the 90:10 
blend. Scanning electron microscopy revealed uniform 
coating. The surface was uneven at low coating level, but 
was uniform in an optimized batch of 25% coating load. 
Dissolution data from stability testing revealed 
that metoprolol succinate was stable with surelease® and 
hydroxypropyl methylcellulose. 
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FIGURE 8 - Scanning electron microscopy of polymer coated 
pellets of an optimized batch F6 (X3000).
FIGURE 9 - Scanning electron microscopy of sustained release 
pellets after compression (X85).
FIGURE 10 - Scanning electron microscopy of sustained release 
pellets after compression X1000).
FIGURE 11 - In vitro dissolution profile of indicating stability 
data of optimized batch F6 after 1 week, 2 weeks, 3 weeks, 1 
month, 2 months and 3 months. Mean (n = 3).
CONCLUSION
In this study, we have shown the effect of varying 
ratios of polymers of Surelease® and HPMC E15 to attain 
the sustained release property of the pellets formulated in 
the multiparticulate tablet using an economical pan coating 
process. In conclusion, the blends of polymer represent 
the potential formulation factor for the sustained release 
rate of highly water soluble drugs avoiding the risk of 
dose dumping.
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